FOXA1 and breast cancer: In contrast, Habashy and colleagues did not find any clinical relevance in the immunohistochemical assessment of FOXA1 in breast cancer routine practice [33], since it was not able to stratify ER-positive (luminal-like) tumours into clinically significant subgroups.